ViroPharma Incorporated Announces Base Share Amount and Auto-Conversion Price for its Plus Cash Notes
May 21, 2004 18:06 ET
|
ViroPharma Incorporated
EXTON, Pa., May 21, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Appoints Colin Broom, M.D. Vice President and Chief Scientific Officer
May 11, 2004 07:34 ET
|
ViroPharma Incorporated
EXTON, Pa., May 11, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that Colin Broom, M.D. has joined the company as vice president and chief scientific officer. Dr. Broom...
ViroPharma Incorporated Reports First Quarter 2004 Financial Results
May 04, 2004 07:35 ET
|
ViroPharma Incorporated
EXTON, Pa., May 4, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) reported today financial results for the first quarter ended March 31, 2004.
Quarter ended March 31, 2004
For the...
ViroPharma Incorporated Commences Exchange Offer for its 6% Convertible Subordinated Notes Due 2007
April 28, 2004 07:30 ET
|
ViroPharma Incorporated
EXTON, Pa., April 28, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Announces Appointment of New Director of Corporate Communications
April 01, 2004 10:00 ET
|
ViroPharma Incorporated
EXTON, Pa., April 1, 2004 (PRIMEZONE) -- ViroPharma, Inc. (Nasdaq:VPHM) announced today the appointment of William C. Roberts as director, corporate communications.
"As ViroPharma goes forward, it...
ViroPharma Announces Filing of Registration Statements for Proposed Exchange Offer with the Holders of its 6% Convertible Subordinated Notes Due 2007 and $25,000,000 New Money Notes Offering
March 19, 2004 18:46 ET
|
ViroPharma Incorporated
EXTON, Pa., March 19, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM), a pharmaceutical company focused on developing and commercializing products that address serious diseases treated by...
ViroPharma Incorporated Enters Into Agreement in Principle to Settle Securities Litigation
March 17, 2004 09:30 ET
|
ViroPharma Incorporated
EXTON, Pa., March 17, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that it has entered into an agreement in principle to settle its current class action securities...
ViroPharma Incorporated Reports 2003 Financial Results
February 25, 2004 08:57 ET
|
ViroPharma Incorporated
EXTON, Pa., Feb. 25, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) reported today financial results for the fourth quarter and the year ended December 31, 2003.
Quarter ended December...
ViroPharma Initiates Phase 1 Hepatitis C Program With HCV-086
February 24, 2004 07:30 ET
|
ViroPharma Incorporated
EXTON, Pa., Feb. 24, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the initiation of a phase 1 clinical program with HCV-086, a hepatitis C antiviral compound that the...
ViroPharma Initiates Clinical Program with Maribavir for Prevention of Cytomegalovirus (CMV) Infection in Transplant Patients
February 05, 2004 07:45 ET
|
ViroPharma Incorporated
EXTON, Pa., Feb. 5, 2004 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced the initiation of a clinical program to develop maribavir, an oral antiviral drug that inhibits...